Aptevo Therapeutics Inc. (APVO)


+0.01 (+2.10%)
Symbol APVO
Price $0.3165
Beta 5.225
Volume Avg. 0.33M
Market Cap 3.647M
Shares () -
52 Week Range 0.3-7.2
1y Target Est -
DCF Unlevered APVO DCF ->
DCF Levered APVO LDCF ->
ROE 142.78% Strong Buy
ROA 90.43% Strong Buy
Operating Margin -
Debt / Equity 35.37% Neutral
P/E -0.09 Neutral
P/B 0.13 Neutral


Consensus EPS

Upgrades & Downgrades

Latest APVO news

Mr. Marvin L. White
NASDAQ Capital Market

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.